title: Comparative Cost-Effectiveness Analysis of Adding Twice-Daily Exenatide To Insulin Glargine Versus Adding Insulin Lispro To Treat Type 2 Diabetes In Spain.
authors.affiliation: AstraZeneca, Madrid, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Sánchez-Covisa
authors.affiliation: AstraZeneca, Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Capel
authors.affiliation: Pharmerit International, Rotterdam, The Netherlands.
authors.forename: S
authors.initials: S
authors.lastname: Baeten
authors.affiliation: Pharmerit International, Rotterdam, The Netherlands.
authors.forename: B G
authors.initials: BG
authors.lastname: Verheggen